Internal Medicine Unit, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy.
Internal Medicine Unit, Felice Lotti Hospital, Pontedera, Azienda USL Toscana Nord-Ovest, Pisa, Italy.
Infect Dis (Lond). 2021 Jul;53(7):479-485. doi: 10.1080/23744235.2021.1905174. Epub 2021 Apr 13.
The duration of immunity after infection from SARS-CoV-2 conferring protection from subsequent COVID-19 episodes is not yet fully understood. We reviewed the literature for cases of documented reinfection.
A comprehensive computerized search in PubMed, through 15 December 2020, using the following terms in combination: To exclude cases due to prolonged viral shedding or protracted infection, only cases occurring at least 12 weeks apart or confirmed as being sustained by genetically different viruses by viral genome analysis were included.
We identified 23 cases globally, for which viral genome analysis was performed in 10 cases and serology in 19 cases. The mean interval between the two episodes was 15 weeks. Mean age of cases was 44.5 years, and 10 (43.5%) were women. In 17/23 cases, no comorbidity was observed. In 10 cases, the first episode was more severe than the ensuing episode, whereas in seven cases the ensuing episode was more severe. In four cases, there was no difference in severity and in two cases both episodes were asymptomatic.
From this sample of 23 cases, a clear pattern of the second episode being less or more severe did not emerge. A better understanding of immunity to SARS-CoV-2, necessary to assess the probability of a second infection and the durability of protection conferred by vaccination, is warranted.
感染 SARS-CoV-2 后产生的免疫持续时间及其对随后 COVID-19 发作的保护作用尚未完全明确。我们对已发表的再感染病例进行了文献回顾。
通过组合使用以下术语,在 PubMed 上进行了全面的计算机检索,检索截至 2020 年 12 月 15 日:为了排除因病毒持续排出或感染迁延导致的病例,仅纳入间隔至少 12 周的病例,或通过病毒基因组分析确认为由遗传上不同病毒引起的持续感染病例。
我们在全球范围内共确定了 23 例病例,其中 10 例进行了病毒基因组分析,19 例进行了血清学分析。两次感染之间的平均间隔为 15 周。病例的平均年龄为 44.5 岁,其中 10 例(43.5%)为女性。在 23 例病例中,17 例未观察到合并症。在 10 例中,首次感染比随后的感染更严重,而在 7 例中,随后的感染更严重。在 4 例中,严重程度无差异,在 2 例中,两次感染均无症状。
从这 23 例病例样本中,并未明确显示第二次感染的严重程度会更低或更高。为了评估再次感染的可能性和疫苗接种提供的保护的持久性,需要更好地了解针对 SARS-CoV-2 的免疫情况。